SG11201706445SA - Enhanced delivery of viral particles to the striatum and cortex - Google Patents
Enhanced delivery of viral particles to the striatum and cortexInfo
- Publication number
- SG11201706445SA SG11201706445SA SG11201706445SA SG11201706445SA SG11201706445SA SG 11201706445S A SG11201706445S A SG 11201706445SA SG 11201706445S A SG11201706445S A SG 11201706445SA SG 11201706445S A SG11201706445S A SG 11201706445SA SG 11201706445S A SG11201706445S A SG 11201706445SA
- Authority
- SG
- Singapore
- Prior art keywords
- striatum
- cortex
- viral particles
- enhanced delivery
- enhanced
- Prior art date
Links
- 210000001577 neostriatum Anatomy 0.000 title 1
- 239000002245 particle Substances 0.000 title 1
- 230000003612 virological effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0085—Brain, e.g. brain implants; Spinal cord
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14151—Methods of production or purification of viral material
- C12N2750/14152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Psychology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562114544P | 2015-02-10 | 2015-02-10 | |
US201562220997P | 2015-09-19 | 2015-09-19 | |
PCT/US2016/017210 WO2016130591A2 (en) | 2015-02-10 | 2016-02-09 | Enhanced delivery of viral particles to the striatum and cortex |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201706445SA true SG11201706445SA (en) | 2017-09-28 |
Family
ID=56614902
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201907399RA SG10201907399RA (en) | 2015-02-10 | 2016-02-09 | Enhanced delivery of viral particles to the striatum and cortex |
SG11201706445SA SG11201706445SA (en) | 2015-02-10 | 2016-02-09 | Enhanced delivery of viral particles to the striatum and cortex |
SG10201912926VA SG10201912926VA (en) | 2015-02-10 | 2016-02-10 | Enhanced delivery of viral particles to the striatum and cortex |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201907399RA SG10201907399RA (en) | 2015-02-10 | 2016-02-09 | Enhanced delivery of viral particles to the striatum and cortex |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201912926VA SG10201912926VA (en) | 2015-02-10 | 2016-02-10 | Enhanced delivery of viral particles to the striatum and cortex |
Country Status (27)
Country | Link |
---|---|
US (2) | US20190111157A1 (zh) |
EP (3) | EP4219728A3 (zh) |
JP (3) | JP6928558B2 (zh) |
KR (2) | KR20240010539A (zh) |
CN (2) | CN107530447A (zh) |
AU (2) | AU2016219398A1 (zh) |
BR (1) | BR112017017037A2 (zh) |
CA (1) | CA2976082A1 (zh) |
CL (1) | CL2017002028A1 (zh) |
CR (1) | CR20170407A (zh) |
DK (1) | DK3256594T3 (zh) |
EA (1) | EA201791803A1 (zh) |
ES (1) | ES2904504T3 (zh) |
HK (1) | HK1246340A1 (zh) |
HU (1) | HUE057272T2 (zh) |
IL (4) | IL296466B1 (zh) |
LT (1) | LT3256594T (zh) |
MX (2) | MX2017010370A (zh) |
PH (1) | PH12017501436A1 (zh) |
PL (1) | PL3256594T3 (zh) |
PT (1) | PT3256594T (zh) |
RS (1) | RS62811B1 (zh) |
SG (3) | SG10201907399RA (zh) |
SI (1) | SI3256594T1 (zh) |
TN (1) | TN2017000353A1 (zh) |
TW (1) | TWI730952B (zh) |
WO (1) | WO2016130591A2 (zh) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015191508A1 (en) | 2014-06-09 | 2015-12-17 | Voyager Therapeutics, Inc. | Chimeric capsids |
CN107106689A (zh) | 2014-11-05 | 2017-08-29 | 沃雅戈治疗公司 | 用于治疗帕金森病的aadc多核苷酸 |
SG11201703419UA (en) | 2014-11-14 | 2017-05-30 | Voyager Therapeutics Inc | Modulatory polynucleotides |
MX2017006216A (es) | 2014-11-14 | 2018-08-29 | Voyager Therapeutics Inc | Composiciones y métodos para tratar la esclerosis lateral amiotrófica (ela). |
EP3230441A4 (en) | 2014-12-12 | 2018-10-03 | Voyager Therapeutics, Inc. | Compositions and methods for the production of scaav |
EA201791803A1 (ru) * | 2015-02-10 | 2017-11-30 | Джензим Корпорейшн | Улучшенная доставка вирусных частиц в полосатое тело и кору больших полушарий |
TWI707951B (zh) | 2015-04-08 | 2020-10-21 | 美商健臻公司 | 過大腺相關載體之製造 |
EP3285788A4 (en) | 2015-04-23 | 2018-12-05 | University of Massachusetts | Modulation of aav vector transgene expression |
GB201508025D0 (en) | 2015-05-11 | 2015-06-24 | Ucl Business Plc | Fabry disease gene therapy |
RU2020126034A (ru) | 2015-09-24 | 2020-09-02 | Байомарин Фармасьютикал Инк. | Векторы фактора fviii на основе аденоассоциированных вирусов, соответствующие вирусные частицы и содержащие их терапевтические композиции |
US11326182B2 (en) | 2016-04-29 | 2022-05-10 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
US11299751B2 (en) | 2016-04-29 | 2022-04-12 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
SG11201809643UA (en) | 2016-05-18 | 2018-12-28 | Voyager Therapeutics Inc | Compositions and methods of treating huntington's disease |
KR102392236B1 (ko) | 2016-05-18 | 2022-05-03 | 보이저 테라퓨틱스, 인크. | 조절성 폴리뉴클레오티드 |
EP3831281A1 (en) | 2016-08-30 | 2021-06-09 | The Regents of The University of California | Methods for biomedical targeting and delivery and devices and systems for practicing the same |
AU2017333336B2 (en) * | 2016-09-30 | 2023-11-09 | Esteve Pharmaceuticals, S.A. | Adenoassociated virus vectors for the treatment of mucopolysaccharidoses |
EP3613856A4 (en) * | 2017-03-31 | 2020-12-23 | Staidson(Beijing) Biopharmaceuticals Co., Ltd. | SHRNA EXPRESSION CASSETTE, POLYNUCLEOTIDE SEQUENCE THEREOF AND THEIR APPLICATION |
MX2019012113A (es) | 2017-04-14 | 2020-09-10 | Univ Nat Taiwan | Terapia génica para la deficiencia de la aadc. |
CA3061652A1 (en) | 2017-05-05 | 2018-11-08 | Voyager Therapeutics, Inc. | Compositions and methods of treating amyotrophic lateral sclerosis (als) |
EP3619308A4 (en) * | 2017-05-05 | 2021-01-27 | Voyager Therapeutics, Inc. | COMPOSITIONS AND METHODS OF TREATMENT FOR HUNTINGTON'S MORBUS |
JOP20190269A1 (ar) | 2017-06-15 | 2019-11-20 | Voyager Therapeutics Inc | بولي نوكليوتيدات aadc لعلاج مرض باركنسون |
JP7229989B2 (ja) | 2017-07-17 | 2023-02-28 | ボイジャー セラピューティクス インコーポレイテッド | 軌道アレイガイドシステム |
KR20200044793A (ko) | 2017-08-03 | 2020-04-29 | 보이저 테라퓨틱스, 인크. | Aav의 전달을 위한 조성물 및 방법 |
JP7502991B2 (ja) | 2017-10-16 | 2024-06-19 | ボイジャー セラピューティクス インコーポレイテッド | 筋萎縮性側索硬化症(als)の治療 |
WO2019079242A1 (en) | 2017-10-16 | 2019-04-25 | Voyager Therapeutics, Inc. | TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) |
CN110876269B (zh) * | 2018-06-29 | 2021-07-30 | 武汉纽福斯生物科技有限公司 | 治疗遗传性视神经病变的组合物和方法 |
EP3880235A4 (en) * | 2018-11-14 | 2022-08-10 | REGENXBIO Inc. | GENE THERAPY OF NEURAL ZEROID LIPOFUSCINOSES |
EP3927381A1 (en) * | 2019-02-22 | 2021-12-29 | The Trustees of The University of Pennsylvania | Recombinant adeno-associated virus for treatment of grn-associated adult-onset neurodegeneration |
EP3983077A4 (en) * | 2019-06-17 | 2023-12-20 | Alnylam Pharmaceuticals, Inc. | DELIVERY OF OLIGONUCLEOTIDES TO THE STRIATUM |
WO2021007382A1 (en) * | 2019-07-09 | 2021-01-14 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of parkinson's disease |
US20220275367A1 (en) * | 2019-07-24 | 2022-09-01 | Voyager Therapeutics, Inc. | Compositions and methods for treating huntington's disease |
US20230399655A1 (en) * | 2020-03-02 | 2023-12-14 | National University Corporation Gunma University | Microglial selective gene expression vector |
EP4093859A4 (en) * | 2020-03-11 | 2023-06-14 | Remotor Therapeutics, Inc. | METHODS AND MATERIALS FOR DISSEMINATING PROTEIN THROUGH THE CENTRAL NERVOUS SYSTEM |
CA3209471A1 (en) * | 2021-01-27 | 2022-08-04 | Research Institute At Nationwide Children's Hospital | Materials and methods for the treatment of lysosomal acid lipase deficiency (lal-d) |
EP4323531A1 (en) | 2021-04-12 | 2024-02-21 | Affinia Therapeutics Inc. | Recombinant aav for treatment of neural disease |
WO2023113806A1 (en) | 2021-12-16 | 2023-06-22 | Affinia Therapeutics, Inc. | Recombinant aav for treatment of neural disease |
WO2023108507A1 (en) * | 2021-12-15 | 2023-06-22 | National Institute Of Biological Sciences, Beijing | Recombinant aav vectors and use thereof |
WO2023109911A1 (en) * | 2021-12-15 | 2023-06-22 | National Institute Of Biological Sciences, Beijing | Microglia having car and use thereof |
WO2024086747A1 (en) | 2022-10-19 | 2024-04-25 | Affinia Therapeutics Inc. | Recombinant aavs with improved tropism and specificity |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4692147A (en) | 1980-04-02 | 1987-09-08 | Medtronic, Inc. | Drug administration device |
US5735815A (en) | 1993-07-26 | 1998-04-07 | Sentinel Medical, Inc. | Method of using fluid jet surgical cutting tool |
EP0931158A1 (en) | 1996-09-06 | 1999-07-28 | The Trustees Of The University Of Pennsylvania | An inducible method for production of recombinant adeno-associated viruses utilizing t7 polymerase |
US6042579A (en) | 1997-04-30 | 2000-03-28 | Medtronic, Inc. | Techniques for treating neurodegenerative disorders by infusion of nerve growth factors into the brain |
US6989264B2 (en) | 1997-09-05 | 2006-01-24 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
US6566118B1 (en) | 1997-09-05 | 2003-05-20 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
CA2329259C (en) * | 1998-05-27 | 2003-08-05 | Avigen, Inc. | Convection-enhanced delivery of aav vectors |
EP1204739B1 (en) | 1999-08-09 | 2008-08-06 | Targeted Genetics Corporation | Enhancement of expression of a single-stranded, heterologous nucleotide sequence from recombinant viral vectors by designing the sequence such that it forms intrastrand base pairs |
NZ522840A (en) | 2000-06-01 | 2004-12-24 | Univ North Carolina | A parvovirus vector that carries a duplexed genome resulting in co-packaging of strands of plus and minus polarity tethered together |
US6723551B2 (en) | 2001-11-09 | 2004-04-20 | The United States Of America As Represented By The Department Of Health And Human Services | Production of adeno-associated virus in insect cells |
NZ532635A (en) | 2001-11-13 | 2007-05-31 | Univ Pennsylvania | A method of identifying unknown adeno-associated virus (AAV) sequences and a kit for the method |
GB2389791B (en) | 2002-04-30 | 2006-12-13 | Steven Gill | Implantable drug delivery pump |
ES2521682T3 (es) | 2003-05-21 | 2014-11-13 | Genzyme Corporation | Procedimientos para producir preparaciones de viriones de AAV recombinantes sustancialmente exentas de cápsidas vacías |
DK1807009T3 (en) | 2004-10-05 | 2015-03-02 | Genzyme Corp | Stair shaped needle |
WO2006119432A2 (en) | 2005-04-29 | 2006-11-09 | The Government Of The U.S.A., As Rep. By The Sec., Dept. Of Health & Human Services | Isolation, cloning and characterization of new adeno-associated virus (aav) serotypes |
EP1879624B1 (en) * | 2005-05-02 | 2011-09-21 | Genzyme Corporation | Gene therapy for neurometabolic disorders |
JP5238503B2 (ja) | 2005-08-23 | 2013-07-17 | ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア | 対流増加送達を用いた治療薬の慢性的な送達のための逆流防止カニューレ及びシステム |
EP2007795B1 (en) | 2006-03-30 | 2016-11-16 | The Board Of Trustees Of The Leland Stanford Junior University | Aav capsid proteins |
BRPI0710800A2 (pt) | 2006-04-25 | 2012-01-17 | Univ California | administração de fatores de crescimento para o tratamento de distúrbios de snc |
WO2007127839A2 (en) | 2006-04-26 | 2007-11-08 | The Regents Of The University Of California | Compositions and methods for convection enhanced delivery of high molecular weight neurotherapeutics |
US11305022B2 (en) | 2009-01-29 | 2022-04-19 | The Regents Of The University Of California | Methods for distributing high levels of therapeutic agent throughout the cortex to treat neurological disorders |
KR101812813B1 (ko) | 2009-06-16 | 2017-12-27 | 젠자임 코포레이션 | 재조합 aav 벡터에 대한 개선된 정제 방법 |
US8663624B2 (en) | 2010-10-06 | 2014-03-04 | The Regents Of The University Of California | Adeno-associated virus virions with variant capsid and methods of use thereof |
US9181544B2 (en) * | 2011-02-12 | 2015-11-10 | University Of Iowa Research Foundation | Therapeutic compounds |
ES2724800T3 (es) | 2011-02-17 | 2019-09-16 | Univ Pennsylvania | Composiciones y métodos para alterar la especificidad de tejido y mejorar la transferencia génica mediada por AAV9 |
EP3137497B1 (en) * | 2014-05-02 | 2021-04-07 | Genzyme Corporation | Aav vectors for retinal and cns gene therapy |
EA201791803A1 (ru) * | 2015-02-10 | 2017-11-30 | Джензим Корпорейшн | Улучшенная доставка вирусных частиц в полосатое тело и кору больших полушарий |
-
2016
- 2016-02-09 EA EA201791803A patent/EA201791803A1/ru unknown
- 2016-02-09 CA CA2976082A patent/CA2976082A1/en active Pending
- 2016-02-09 MX MX2017010370A patent/MX2017010370A/es unknown
- 2016-02-09 IL IL296466A patent/IL296466B1/en unknown
- 2016-02-09 EP EP23150591.8A patent/EP4219728A3/en active Pending
- 2016-02-09 DK DK16714066.4T patent/DK3256594T3/da active
- 2016-02-09 ES ES16714066T patent/ES2904504T3/es active Active
- 2016-02-09 SI SI201631446T patent/SI3256594T1/sl unknown
- 2016-02-09 CN CN201680020700.4A patent/CN107530447A/zh active Pending
- 2016-02-09 KR KR1020247000976A patent/KR20240010539A/ko active Application Filing
- 2016-02-09 SG SG10201907399RA patent/SG10201907399RA/en unknown
- 2016-02-09 LT LTEPPCT/US2016/017210T patent/LT3256594T/lt unknown
- 2016-02-09 RS RS20220044A patent/RS62811B1/sr unknown
- 2016-02-09 JP JP2017560479A patent/JP6928558B2/ja active Active
- 2016-02-09 HU HUE16714066A patent/HUE057272T2/hu unknown
- 2016-02-09 AU AU2016219398A patent/AU2016219398A1/en not_active Abandoned
- 2016-02-09 PT PT167140664T patent/PT3256594T/pt unknown
- 2016-02-09 WO PCT/US2016/017210 patent/WO2016130591A2/en active Application Filing
- 2016-02-09 TN TNP/2017/000353A patent/TN2017000353A1/en unknown
- 2016-02-09 EP EP21198081.8A patent/EP4023758A1/en not_active Withdrawn
- 2016-02-09 PL PL16714066T patent/PL3256594T3/pl unknown
- 2016-02-09 CR CR20170407A patent/CR20170407A/es unknown
- 2016-02-09 CN CN202210805297.3A patent/CN116019934A/zh active Pending
- 2016-02-09 EP EP16714066.4A patent/EP3256594B1/en active Active
- 2016-02-09 US US15/549,962 patent/US20190111157A1/en not_active Abandoned
- 2016-02-09 SG SG11201706445SA patent/SG11201706445SA/en unknown
- 2016-02-09 BR BR112017017037A patent/BR112017017037A2/pt active Search and Examination
- 2016-02-09 KR KR1020177025285A patent/KR102625784B1/ko active IP Right Grant
- 2016-02-09 IL IL313840A patent/IL313840A/en unknown
- 2016-02-10 SG SG10201912926VA patent/SG10201912926VA/en unknown
- 2016-02-15 TW TW105104342A patent/TWI730952B/zh active
-
2017
- 2017-08-08 CL CL2017002028A patent/CL2017002028A1/es unknown
- 2017-08-08 IL IL253894A patent/IL253894B/en unknown
- 2017-08-10 PH PH12017501436A patent/PH12017501436A1/en unknown
- 2017-08-10 MX MX2021004294A patent/MX2021004294A/es unknown
-
2018
- 2018-04-25 HK HK18105355.8A patent/HK1246340A1/zh unknown
-
2021
- 2021-07-22 IL IL285060A patent/IL285060B2/en unknown
- 2021-08-06 JP JP2021129519A patent/JP2021178861A/ja active Pending
-
2022
- 2022-06-28 AU AU2022204583A patent/AU2022204583A1/en active Pending
- 2022-07-29 US US17/816,139 patent/US20220395586A1/en active Pending
-
2023
- 2023-02-10 JP JP2023018846A patent/JP2023058630A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL285060A (en) | Increased transmission of viral particles to the striatum and cortex | |
IL258723A (en) | A particle and a system for creating a spray containing such particles | |
HK1253018A1 (zh) | 紫杉烷顆粒及其用途 | |
IL266679A (en) | administration of neoantigens in the virus | |
IL259894A (en) | Improved compositions and improved methods for viral delivery of neoepitopes and their use | |
ZA201704662B (en) | Friable ceramic-bonded diamond composite particles and methods to produce same | |
IL260022A (en) | Preparation of respirable zafirlukast particles | |
ZA201605492B (en) | Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same | |
HK1256875A1 (zh) | 加强對大腦的藥物輸送 | |
EP3356472C0 (en) | PARTICLE SURFACE TREATMENT | |
GB201522512D0 (en) | Flourescent diamond particles and methods of fabricating the same | |
PL3233233T3 (pl) | Kompozycje odpieniające zawierające cząstki amfifilowe i sposoby ich stosowania | |
SG11201704486TA (en) | Improvements in and relating to the treatment of matrices and/or the contents of matrices | |
HK1248652A1 (zh) | 由漿滴製造支撐劑顆粒的方法及支撐劑顆粒的使用方法 | |
ZA201801211B (en) | Cleaning particles and their use | |
HK1254366A1 (zh) | 由漿滴形成的支撐劑顆粒及其使用方法 | |
GB201421261D0 (en) | Improvements in and relating to the processing of matrices and/or the contents of matrices | |
GB201402556D0 (en) | Improvements relating to inhalable particles | |
GB2545716B (en) | Improvements in or relating to the separation of radon | |
GB201517790D0 (en) | Preparation of inhalable particles | |
GB201517030D0 (en) | Preparation of articles comprising graphitic particles | |
GB201520019D0 (en) | The genome and self-evolution of AI | |
GB201504861D0 (en) | Viral particle based RNA Interaction Trap |